NCT05121363View on ClinicalTrials.gov

A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma

PHASE2UnknownINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

December 31, 2021

Primary Completion Date

May 31, 2023

Study Completion Date

July 31, 2023

Conditions
Endometrial Carcinoma
Interventions
DRUG

TQB2858 injection

TQB2858 is an anti-programmed death receptor 1(anti-PD-1) /Transforming growth factor-β(TGF-β )bi-functional fusion protein

DRUG

Anlotinib Hydrochloride capsules

Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.

Trial Locations (2)

250012

Qilu Hospital of Shandong University, Jinan

410013

Hunan Cancer Hospita, Changsha

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY